{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T01:31:44Z","timestamp":1781227904831,"version":"3.54.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1124\/jpet.111.184093","type":"journal-article","created":{"date-parts":[[2011,7,23]],"date-time":"2011-07-23T02:07:13Z","timestamp":1311386833000},"page":"2-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Anatomically Selective Serotonergic Type 1A and Serotonergic Type 2A Therapies for Parkinson\u2019s Disease: An Approach to Reducing Dyskinesia without Exacerbating Parkinsonism?"],"prefix":"10.1016","volume":"339","author":[{"given":"Philippe","family":"Huot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan H.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Newman-Tancredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.111.184093_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0006-8993(99)01224-X","article-title":"Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release","volume":"825","author":"Aghajanian","year":"1999","journal-title":"Brain Res"},{"key":"10.1124\/jpet.111.184093_bib2","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","article-title":"A review of central 5-HT receptors and their function","volume":"38","author":"Barnes","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.111.184093_bib3","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/mds.10551","article-title":"Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson\u2019s disease","volume":"18","author":"Baron","year":"2003","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.111.184093_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00702-003-0094-7","article-title":"Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile","volume":"111","author":"Bartoszyk","year":"2004","journal-title":"J Neural Transm"},{"key":"10.1124\/jpet.111.184093_bib5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ddstr.2006.10.017","article-title":"Development of functionally selective agonists as novel therapeutic agents","volume":"3","author":"Berg","year":"2006","journal-title":"Drug Discov Today Ther Strat"},{"key":"10.1124\/jpet.111.184093_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00002826-199402000-00008","article-title":"Buspirone in levodopa-induced dyskinesias","volume":"17","author":"Bonifati","year":"1994","journal-title":"Clin Neuropharmacol"},{"key":"10.1124\/jpet.111.184093_bib7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2006.01.027","article-title":"Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase","volume":"534","author":"Bruins Slot","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.111.184093_bib8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/1098-2396(20010315)39:4<297::AID-SYN1012>3.0.CO;2-Q","article-title":"Distribution of serotonin 5-HT2A receptors in afferents of the rat striatum","volume":"39","author":"Bubser","year":"2001","journal-title":"Synapse"},{"key":"10.1124\/jpet.111.184093_bib9","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.neuropharm.2008.09.004","article-title":"Region-specific changes in 5-HT1A agonist-induced extracellular signal-regulated kinases 1\/2 phosphorylation in rat brain: a quantitative ELISA study","volume":"56","author":"Buritova","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.111.184093_bib10","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1471-4159.2005.03600.x","article-title":"The 5-HT1A receptor agonist 8-OH-DPAT prevents prefrontocortical glutamate and serotonin release in response to blockade of cortical NMDA receptors","volume":"96","author":"Calcagno","year":"2006","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.111.184093_bib11","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"10.1124\/jpet.111.184093_bib12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0079-6123(08)00922-9","article-title":"Serotonin-dopamine interaction in the induction and maintenance of l-DOPA-induced dyskinesias","volume":"172","author":"Carta","year":"2008","journal-title":"Prog Brain Res"},{"key":"10.1124\/jpet.111.184093_bib13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0014-2999(02)02297-5","article-title":"5-HT1A receptor-mediated regulation of mitogen-activated protein kinase phosphorylation in rat brain","volume":"452","author":"Chen","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.111.184093_bib14","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0022-3565(25)13071-1","article-title":"Lack of 5-hydroxytryptamine1A-mediated inhibition of adenylyl cyclase in dorsal raphe of male and female rats","volume":"277","author":"Clarke","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.184093_bib15","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0026-895X(25)11082-1","article-title":"Intrinsic activity of enantiomers of 8-hydroxy-2-(di-n-propylamino)tetralin and its analogs at 5-hydroxytryptamine1A receptors that are negatively coupled to adenylate cyclase","volume":"39","author":"Cornfield","year":"1991","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.111.184093_bib16","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1471-4159.2005.03107.x","article-title":"5-HT receptors couple to activation of Akt, but not extracellular-regulated kinase (ERK), in cultured hippocampal neurons","volume":"93","author":"Cowen","year":"2005","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.111.184093_bib17","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1176\/appi.ajp.161.4.739","article-title":"Serotonin1A receptors at the axon initial segment of prefrontal pyramidal neurons in schizophrenia","volume":"161","author":"Cruz","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1124\/jpet.111.184093_bib18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejphar.2008.07.040","article-title":"Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq\/11 activation and calcium mobilisation in CHO cells","volume":"594","author":"Cussac","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.111.184093_bib19","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","article-title":"Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model","volume":"179","author":"Dekundy","year":"2007","journal-title":"Behav Brain Res"},{"key":"10.1124\/jpet.111.184093_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/archneur.64.1.20","article-title":"Circuits and circuit disorders of the basal ganglia","volume":"64","author":"DeLong","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1124\/jpet.111.184093_bib21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.expneurol.2011.02.012","article-title":"Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats","volume":"229","author":"Dupre","year":"2011","journal-title":"Exp Neurol"},{"key":"10.1124\/jpet.111.184093_bib22","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0028-3908(99)00033-7","article-title":"Modulation of 5-HT1A receptor signalling by point-mutation of cysteine351 in the rat G\u03b1o protein","volume":"38","author":"Dupuis","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.111.184093_bib23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","article-title":"Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study","volume":"62","author":"Durif","year":"2004","journal-title":"Neurology"},{"issue":"Suppl 3","key":"10.1124\/jpet.111.184093_bib24","doi-asserted-by":"crossref","first-page":"S497","DOI":"10.1002\/mds.22028","article-title":"The history of dopamine and levodopa in the treatment of Parkinson\u2019s disease","volume":"23","author":"Fahn","year":"2008","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.111.184093_bib25","series-title":"Society for Neuroscience Annual Meeting; 2010 Nov. 13\u201317; San Diego, CA","article-title":"5-HT2A receptor antagonist M100907 decreases striatal extracellular glutamate in MPTP mouse model of Parkinson\u2019s disease","author":"Ferguson","year":"2010"},{"key":"10.1124\/jpet.111.184093_bib26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0014-2999(96)00100-8","article-title":"Normethylclozapine potentiates the action of quinpirole in the 6-hydroxydopamine lesioned rat","volume":"301","author":"Fox","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.111.184093_bib27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","article-title":"Sarizotan as a treatment for dyskinesias in Parkinson\u2019s disease: a double-blind placebo-controlled trial","volume":"22","author":"Goetz","year":"2007","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.111.184093_bib28","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/mds.21897","article-title":"Placebo influences on dyskinesia in Parkinson\u2019s disease","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.111.184093_bib29","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.parkreldis.2008.11.001","article-title":"Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-Dopa in parkinsonian monkeys","volume":"15","author":"Gr\u00e9goire","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1124\/jpet.111.184093_bib30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0006-3223(90)90627-E","article-title":"Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites","volume":"28","author":"Hamik","year":"1990","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.111.184093_bib31","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney Multicenter Study of Parkinson\u2019s disease: non-l-dopa-responsive problems dominate at 15 years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.111.184093_bib32","article-title":"Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque","author":"Huot","year":"2010","journal-title":"Neurobiol Aging"},{"key":"10.1124\/jpet.111.184093_bib33","article-title":"5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with l-DOPA","author":"Huot","year":"2010","journal-title":"Neurobiol Aging"},{"key":"10.1124\/jpet.111.184093_bib34","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1124\/jpet.106.110429","article-title":"In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability","volume":"319","author":"Iravani","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.184093_bib35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-2999(97)10113-3","article-title":"[3H]8-OH-DPAT labels a 5-HT site coupled to inhibition of phosphoinositide hydrolysis in the dorsal raphe","volume":"329","author":"Johnson","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.111.184093_bib36","first-page":"133","article-title":"[Tandospirone citrate, a selective 5-HT1A agonist, alleviates l-DOPA-induced dyskinesia in patients with Parkinson\u2019s disease]","volume":"54","author":"Kannari","year":"2002","journal-title":"No To Shinkei"},{"key":"10.1124\/jpet.111.184093_bib37","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1124\/jpet.110.173948","article-title":"Functional selectivity and biased receptor signaling","volume":"336","author":"Kenakin","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.184093_bib38","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0022-3565(24)36532-2","article-title":"Interactions of (+)- and (\u2212)-8- and 7-hydroxy-2-(di-n-propylamino)tetralin at human (h)D3, hD2, and h serotonin1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats","volume":"280","author":"Lejeune","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.184093_bib39","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0026-895X(25)12558-3","article-title":"Receptor-binding properties in vitro and in vivo of ritanserin: a very potent and long acting serotonin-S2 antagonist","volume":"27","author":"Leysen","year":"1985","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.111.184093_bib40","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1111\/j.1476-5381.2010.00738.x","article-title":"Preferential in vivo action of F15599, a novel 5-HT1A receptor agonist, at postsynaptic 5-HT1A receptors","volume":"160","author":"Llad\u00f3-Pelfort","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.111.184093_bib41","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1046\/j.1471-4159.2000.740693.x","article-title":"Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum","volume":"74","author":"Lucas","year":"2000","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.111.184093_bib42","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00002826-198608000-00004","article-title":"Buspirone, Parkinson\u2019s disease, and the locus ceruleus","volume":"9","author":"Ludwig","year":"1986","journal-title":"Clin Neuropharmacol"},{"key":"10.1124\/jpet.111.184093_bib43","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/00002826-198610000-00010","article-title":"Open pilot trial of ritanserin in parkinsonism","volume":"9","author":"Maertens de Noordhout","year":"1986","journal-title":"Clin Neuropharmacol"},{"key":"10.1124\/jpet.111.184093_bib44","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1124\/mol.106.022756","article-title":"Regional differences in the coupling of 5-hydroxytryptamine-1A receptors to G proteins in the rat brain","volume":"70","author":"Mannoury la Cour","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.111.184093_bib45","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00213-008-1452-9","article-title":"Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats","volume":"204","author":"Marin","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.111.184093_bib46","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0893-133X(00)00187-1","article-title":"Differential occupancy of somatodendritic and postsynaptic 5HT1A receptors by pindolol: a dose-occupancy study with [1C]WAY 100635 and positron emission tomography in humans","volume":"24","author":"Martinez","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.111.184093_bib47","first-page":"262","article-title":"Controlled single-blind crossover study of ritanserin and placebo in L-dopa-induced dyskinesias in Parkinson\u2019s disease","volume":"43","author":"Meco","year":"1988","journal-title":"Curr Ther Res"},{"key":"10.1124\/jpet.111.184093_bib48","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/BF02272148","article-title":"5-HT receptors in mammalian brain: receptor autoradiography and in situ hybridization studies of new ligands and newly identified receptors","volume":"28","author":"Mengod","year":"1996","journal-title":"Histochem J"},{"key":"10.1124\/jpet.111.184093_bib49","first-page":"S221","article-title":"A double-blind, placebo-controlled, dose-escalation trial of pimavanserin in Parkinson\u2019s disease and psychosis","volume":"23","author":"Mills","year":"2008","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.111.184093_bib50","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0166-4328(96)00111-8","article-title":"Ca2+ mobilizing agents mimic serotonin 5-HT2A facilitation of N-methyl-d-aspartate depolarization","volume":"73","author":"Neuman","year":"1996","journal-title":"Behav Brain Res"},{"key":"10.1124\/jpet.111.184093_bib51","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2217\/npy.11.12","article-title":"Biased agonism at serotonin 5-HT1A receptors: preferential postsynaptic activity for improved therapy of CNS disorders","volume":"1","author":"Newman-Tancredi","year":"2011","journal-title":"Neuropsychiatry"},{"key":"10.1124\/jpet.111.184093_bib52","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1017\/S1461145704005000","article-title":"Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia","volume":"8","author":"Newman-Tancredi","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1124\/jpet.111.184093_bib53","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0014-2999(98)00483-X","article-title":"Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTP\u03b3S binding study","volume":"355","author":"Newman-Tancredi","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.111.184093_bib54","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00213-011-2247-y","article-title":"Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties","volume":"216","author":"Newman-Tancredi","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.111.184093_bib55","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1476-5381.2008.00001.x","article-title":"Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist","volume":"156","author":"Newman-Tancredi","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.111.184093_bib56","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1176\/ajp.152.10.1444","article-title":"D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients","volume":"152","author":"Nordstr\u00f6m","year":"1995","journal-title":"Am J Psychiatry"},{"key":"10.1124\/jpet.111.184093_bib57","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-200403000-00003","article-title":"Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study)","volume":"27","author":"Olanow","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"10.1124\/jpet.111.184093_bib58","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.neuropharm.2011.05.021","article-title":"Role of the primary motor cortex in l-DOPA-induced dyskinesia and its modulation by 5-HT1A receptor stimulation","volume":"61","author":"Ostock","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.111.184093_bib59","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00441-005-1112-x","article-title":"5-HT1A receptor expression in pyramidal neurons of cortical and limbic brain regions","volume":"321","author":"Palchaudhuri","year":"2005","journal-title":"Cell Tissue Res"},{"key":"10.1124\/jpet.111.184093_bib60","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.npp.1300819","article-title":"Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex","volume":"31","author":"Pehek","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.111.184093_bib61","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0169-328X(94)90223-2","article-title":"Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors","volume":"23","author":"Pompeiano","year":"1994","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1124\/jpet.111.184093_bib62","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/026988110201600301","article-title":"Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride","volume":"16","author":"Rabiner","year":"2002","journal-title":"J Psychopharmacol"},{"key":"10.1124\/jpet.111.184093_bib63","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/mds.10176","article-title":"The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia","volume":"17","author":"Reddy","year":"2002","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.111.184093_bib64","first-page":"653","article-title":"ACP-103, a 5-HT2A receptor inverse agonist","volume":"7","author":"Roberts","year":"2006","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1124\/jpet.111.184093_bib65","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/cercor\/bhh070","article-title":"Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex","volume":"14","author":"Santana","year":"2004","journal-title":"Cereb Cortex"},{"key":"10.1124\/jpet.111.184093_bib66","doi-asserted-by":"crossref","first-page":"13513","DOI":"10.1523\/JNEUROSCI.1665-10.2010","article-title":"Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a \u03b2-arrestin2\/Src\/Akt signaling complex in vivo","volume":"30","author":"Schmid","year":"2010","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.111.184093_bib67","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1073\/pnas.0708862105","article-title":"Agonist-directed signaling of the serotonin 2A receptor depends on \u03b2-arrestin-2 interactions in vivo","volume":"105","author":"Schmid","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1124\/jpet.111.184093_bib68","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mds.10394","article-title":"Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure","volume":"18","author":"Smith","year":"2003","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.111.184093_bib69","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0028-3908(88)90079-2","article-title":"Responses of hippocampal pyramidal cells to putative serotonin 5-HT1A and 5-HT1B agonists: a comparative study with dorsal raphe neurons","volume":"27","author":"Sprouse","year":"1988","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.111.184093_bib70","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1124\/jpet.107.123729","volume":"322","author":"Tamaoki","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.184093_bib71","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.pbb.2008.04.010","article-title":"A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model","volume":"90","author":"Vanover","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.111.184093_bib72","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1124\/jpet.105.097006","article-title":"Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N\u2032-(4-(2-methylpropyloxy)phenylmethyl)carbamide(2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist","volume":"317","author":"Vanover","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.184093_bib73","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/mds.21073","article-title":"Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson\u2019s disease","volume":"21","author":"Visanji","year":"2006","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.111.184093_bib74","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF02245441","article-title":"An open clinical and biochemical study of ritanserin in acute patients with schizophrenia","volume":"114","author":"Wiesel","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.111.184093_bib75","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/(SICI)1098-2396(199709)27:1<79::AID-SYN8>3.0.CO;2-A","article-title":"Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex","volume":"27","author":"Willins","year":"1997","journal-title":"Synapse"},{"key":"10.1124\/jpet.111.184093_bib76","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1212\/WNL.40.5.832","article-title":"Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis","volume":"40","author":"Wolters","year":"1990","journal-title":"Neurology"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524465567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524465567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.111.184093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T02:35:52Z","timestamp":1740018952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524465567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0022356524465567"],"URL":"https:\/\/doi.org\/10.1124\/jpet.111.184093","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anatomically Selective Serotonergic Type 1A and Serotonergic Type 2A Therapies for Parkinson\u2019s Disease: An Approach to Reducing Dyskinesia without Exacerbating Parkinsonism?","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.111.184093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2011 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}